Welcome to Jext®

Please select the section of the website that is relevant to you.

If you have been given a Jext® 300 mcg adrenaline auto-injector in a foreign language, please click here for further information.

You may be aware of the recent supply issues affecting some brands of adrenaline auto-injectors, which have resulted in increased demands on alternative brands of autoinjectors including Jext®. To support and maintain an overall adequate supply, ALK has obtained acceptance from the UK medicines regulator, Medicines and Healthcare Regulatory Agency (MHRA) to import a quantity of Jext® 300mcg devices from Austria. This device is equivalent to the device normally supplied in the United Kingdom but has Austrian language packaging and labelling. It should be supplied to you with a Patient Information Leaflet in English.

You can find further information on how to use Jext® by visiting www.jext.co.uk; which also includes training videos and further information as well as how to order Jext® training devices. Additionally, the Jext® app can be downloaded for iPhone and Android which also contains information on how to use Jext®.

This only applies to Jext® 300mcg in the following batch numbers: B4509, B4587, B4813, B4722 and B4727.

Further information for Patients

  • You should retain the English language UK Patient Information Leaflet supplied with the product.
  • You can find additional information on how to use Jext® and order training devices on www.jext.co.uk.
  • You can be confident that your device is equivalent to the UK product and will work in exactly the same way.
  • You should obtain a new device near the end of the month of expiry marked on the box and device. You are encouraged to sign up for the Expiry Alert Service.
  • You should continue to check periodically the viewing window in the label of their device to ensure the liquid inside is clear and colourless. Do not use the device if the liquid is discoloured.
  • You should consult your doctor or pharmacist if you have any concerns regarding this announcement. ALK cannot give specific treatment advice to patients.

If you require additional information or have any questions, please contact ALK Customer Services: 0118 903 7940.

1391AD

Date of Preparation: 14th October 2019

Supply of Jext® / Extended Use Beyond Labelled Expiry Date for Selected Lots of Jext® 150 mcg and 300 mcg Adrenaline Auto-Injectors

Supply of Jext® (adrenaline as tartrate) 150 mcg and 300 mcg Adrenaline Auto-Injector

You may be aware of the recent supply issues affecting some brands of adrenaline auto-injectors, which have resulted in increased demands on alternative brands of auto-injectors including Jext®.  The overall market supply of adrenaline auto-injectors is being monitored by the Department of Health and Social Care.

ALK is working hard to help address the situation and has significantly increased production of its Jext® 150 mcg and 300 mcg adrenaline auto-injectors at its European manufacturing facility. However, due to the time needed for manufacture and the magnitude of the current deficit, it is not possible for ALK to completely meet the shortfall in supply in the short term.

ALK is working closely with its UK distribution partner Alliance Healthcare to ensure equitable distribution of supplies but it is likely that Jext® 150 mcg and Jext® 300 mcg will not be available at all times.

Extended Use Beyond Labelled Expiry Date for Selected Lots of Jext® 150 mcg and 300 mcg Adrenaline Auto-Injectors

To support and maintain an overall adequate supply, ALK has obtained acceptance from the UK medicines regulator, Medicines and Healthcare Products Regulatory Agency (MHRA), to extend the use of specific lot (batch) numbers of Jext® 150 mcg and Jext® 300 mcg auto-injectors, beyond the labelled expiry date by four months. The affected lot numbers are listed in the table below.

Table 1            Affected lots (batches) for extended use of Jext® auto-injectors

No. Strength, mcg Lot (batch) no. Labelled Expiry Date (end of the month) Extended Use by Date (end of the month)
1 150 A5263 Sep 2019 Jan 2020
2 150 A5682 Sep 2019 Jan 2020
3 150 A5713 Sep 2019 Jan 2020
4 150 A5848 Sep 2019 Jan 2020
5 150 A5850 Oct 2019 Feb 2020
6 150 A6014 Oct 2019 Feb 2020
7 150 A6244 Nov 2019 Mar 2020
8 150 A6705 Nov 2019 Mar 2020
9 150 A6934 Dec 2019 Apr 2020
10 150 A7052 Nov 2019 Mar 2020
11 150 A7082 Nov 2019 Mar 2020
12 150 A7237 Dec 2019 Apr 2020
13 150 A7317 Dec 2019 Apr 2020
14 150 A7403 Dec 2019 Apr 2020
15 150 A7505 Dec 2019 Apr 2020
16 150 B3313 Dec 2019 Apr 2020
17 300 A5198 Aug 2019 Dec 2019
18 300 A5283 Aug 2019 Dec 2019
19 150 A5364 Sep 2019 Jan 2020
20 300 A5501 Sep 2019 Jan 2020
21 300 A5676 Sep 2019 Jan 2020
22 300 A5793 Sep 2019 Jan 2020
23 300 A5994 Sep 2019 Jan 2020
24 300 A5910 Oct 2019 Feb 2020
25 300 A5988 Oct 2019 Feb 2020
26 300 A6074 Oct 2019 Feb 2020
27 300 A6148 Nov 2019 Mar 2020
28 300 A6330 Nov 2019 Mar 2020
29 300 A6569 Nov 2019 Mar 2020
30 300 A6848 Nov 2019 Mar 2020
31 300 A6862 Dec 2019 Apr 2020
32 300 A7095 Dec 2019 Apr 2020
33 300 A7215 Dec 2019 Apr 2020
34 300 A7232 Dec 2019 Apr 2020
35 300 A7329 Dec 2019 Apr 2020
36 300 A7393 Dec 2019 Apr 2020
37 300 A7395 Dec 2019 Apr 2020
38 300 A7511 Dec 2019 Apr 2020
39 300 B3042 Dec 2019 Apr 2020
40 300 B3141 Dec 2019 Apr 2020

Important: the extended use only applies to the lots of Jext® 150 mcg and Jext® 300 mcg auto-injectors listed above. 

This extended use does not apply to any other lot number of Jext® auto-injectors not specified. Patients must continue to adhere to the labelled expiry date on any Jext® auto-injector not covered by the lot numbers above.

This extended use of 4 months beyond the labelled expiry date for the specific lots is based on supportive stability data for Jext® auto-injectors and has been reviewed by the MHRA.  The Jext® auto-injectors of these specific lots will continue to work safely and as intended within the allowed extended use by date.

This announcement regarding the extended use of certain batches supersedes any notification that a patient may receive via the expiry alert service from www.jext.co.uk.

Supply of Jext® / Information for Patients

  • Lot numbers and labelled expiry dates are marked on the end-flap of the box and on the auto-injector label itself.
  • The specified lots of Jext® 150 mcg and 300 mcg auto-injectors will continue to work safely over the extended use period beyond the labelled expiry date.
  • If you are unsure whether your Jext® auto-injector is affected, talk to your pharmacist.
  • The Jext® auto-injectors should continue to be stored as labelled on the pack.
  • Towards the end of the extended use period (the end of the month listed in the right column of the table above), a new auto-injector will still need to be obtained.
  • You should continue to check periodically the viewing window in the label of your auto-injector to ensure that the liquid inside is clear and colourless. Do not use the auto-injector if the liquid is discoloured.
  • You should consult your doctor or pharmacist if you have any concerns regarding this announcement. ALK cannot give specific treatment advice to patients.

If you require additional information or have any questions, please contact ALK Customer Services: 0118 903 7940.

1386AD

Date of Preparation: 21st September 2019